Title :

Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal alzheimer's disease

Author(s) :

Teipel, Stefan J. [Auteur]
Cavedo, Enrica [Auteur]
Grothe, Michel J. [Auteur]
Lista, Simone [Auteur]
Galluzzi, Samantha [Auteur]
Colliot, Olivier [Auteur]
Chupin, Marie [Auteur]
Bakardjian, Hovagim [Auteur]
Dormont, Didier [Auteur]
Dubois, Bruno [Auteur]
Hampel, Harald [Auteur]

Journal title :

Neuropharmacology

Abbreviated title :

Neuropharmacology

Volume number :

108

Pages :

128-35

Publication date :

2016-09-01

ISSN :

1873-7064

English keyword(s) :

Hippocampus
MRI
Cholinesterase inhibitors
Cognitive decline
MCI
Prodromal Alzheimer''s disease
Therapy
Prediction
Cholinergic system
Biomarkers
Basal forebrain

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers ...
Show more >We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up. Outcome measures were the rates of global and domain specific cognitive decline as non-primary efficacy endpoint. The intention-to-treat (ITT) sample analyzed comprised 215 cases. Baseline Hp volume was a significant predictor of rates of change in global cognitive function in linear mixed effects models. This effect was independent of treatment. BF volume was not associated with rates of global or domain specific cognitive decline. Rates of delayed free recall decline were higher in MCI cases treated with donepezil compared to placebo. Only Hp, but not BF volume was a useful predictor of cognitive decline in suspected prodromal AD patients. Both Hp and BF volumes were poor predictors of treatment response, questioning previous approaches on predicting treatment response without placebo control. clinicalTrials.gov Identifier NCT00403520.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T13:36:35Z